Deerfield Management Company L.P. Series C Acquires Shares of 19,456 Twist Bioscience Co. (NASDAQ:TWST)

Deerfield Management Company L.P. Series C acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 19,456 shares of the company’s stock, valued at approximately $959,000.

Other large investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares during the last quarter. Norges Bank acquired a new position in Twist Bioscience during the fourth quarter worth about $10,766,000. UBS Group AG grew its stake in Twist Bioscience by 106.4% during the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after acquiring an additional 110,036 shares in the last quarter. Franklin Resources Inc. grew its stake in Twist Bioscience by 1.3% during the 4th quarter. Franklin Resources Inc. now owns 173,924 shares of the company’s stock valued at $6,411,000 after acquiring an additional 2,263 shares in the last quarter. Finally, Evoke Wealth LLC acquired a new stake in Twist Bioscience in the 4th quarter valued at about $572,000.

Twist Bioscience Stock Up 3.1 %

TWST opened at $47.08 on Friday. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90. The business has a fifty day simple moving average of $46.46 and a 200-day simple moving average of $43.24. The firm has a market cap of $2.76 billion, a P/E ratio of -14.01 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) earnings per share. Sell-side analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total transaction of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares of the company’s stock, valued at $24,227,136. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $205,200.27. Following the sale, the chief executive officer now directly owns 499,593 shares in the company, valued at $19,948,748.49. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,114 shares of Twist Bioscience stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now directly owns 504,732 shares of the company’s stock, valued at $24,227,136. The disclosure for this sale can be found here. Insiders have sold a total of 17,386 shares of company stock valued at $770,915 in the last ninety days. Company insiders own 3.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TWST shares. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Guggenheim started coverage on Twist Bioscience in a research note on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. Barclays cut their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Robert W. Baird upped their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Finally, The Goldman Sachs Group increased their price target on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.